Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз)

По инициативе российского национального гематологического общества (председатель: главный гематолог-трансфузиолог Минздрава России, акад. РАН, директор ФГБУ Гематологический научный центр Минздрава России, проф. В.Г.Савченко), исследовательской группы по изучению миелопролиферативных заболеваний разработаны клинические рекомендации по диагностике и лечению классических Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз, миелопролиферативное заболевание, неклассифицированное, постполицитемический и посттромбоцитемический миелофиброз). Цель рекомендаций - стандартизация диагностических и лечебных подходов в России. Используемые методологические подходы основаны на принципах доказательной медицины, в их основе лежат рекомендации Европейской организации по изучению и лечению лейкозов (European Leukemia Net, ELN), Национальной онкологической сети (NCCN) США, Международной рабочей группы по исследованию и терапии миелопролиферативных заболеваний (international working group-myeloproliferative neoplasm research and treatment, IWG-MRT), а также российский опыт ведения больных миелопролиферативными заболеваниями. Рекомендации разработаны Многоцентровой исследовательской группой по изучению миелопролиферативных заболеваний. В разработке клинических рекомендаций принимали участие сотрудники 10 ведущих учреждений.

Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937-51.

Rollison D.E., Howlader N., Smith M.T., Strom S.S., Merritt W.D., Ries L.A., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45-52.

Tefferi F. the history of myeloproliferative disorders: before and after Dameshek. Leykemia. 2008; 22(1): 3-13.

Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6): 2162-8.

Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366(9501): 1945-53.

Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2 V617F Era. Hematology Am. Soc. Hematol. Educ. Program. 2006: 240-5.

Vannucchi A.M., Pieri L., Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther. Adv. Hematol. 2011; 2(1): 21-32. doi: 10.1177/2040620710394474.

Pardanani A., Lasho T.L., Finke C., Hanson C.A., Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007; 21(9): 1960-3.

Vannucchi A.M., Antonioli E., Guglielmelli P., Pardanani A., Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008; 22(7): 1299-307.

Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C. A., et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007; 110(4): 1092-7.

Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J. Clin. Oncol. 2005; 23(33): 8520-30.

Campbell P.J., Scott L.M., Baxter E.J., Bench A.J., Green A.R., Erber W.N. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol. Med. 2006; 125: 253-64.

Pardanani A., Lasho T.L., Finke C.M., Tefferi A. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am. J. Hematol. 2011; 86(8): 701-2. doi: 10.1002/ ajh.22058.

Ohashi H., Arita K., Fukami S., Oguri K., Nagai H., Yokozawa T., et al. Two rare MPL gene mutations in patients with essential thrombocythemia. Int. J. Hematol. 2009; 90(3): 431-2.

Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood. 2008; 112(1): 141-9. doi:10.1182/blood-2008-01-131664

Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., et al. Familial essential thrombocythemia associated with a dominantpositive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004; 103(11): 4198-200.

Liu K., Martini M., Rocca B., Amos C.I., Teofili L., Giona F., et al. Evidence for a founder effect of the MPLS505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009; 94(10): 1368-74. doi: 10.3324/haematol.2009.005918

Pardanani A., Guglielmelli P., Lasho T.L. Pancrazzi A., Finke C.M., Vannucchi A.M. et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011; 25(12): 1834-9. doi:10.1038/leu.2011.161

Vannucchi A.M., Antonioli E., Guglielmelli P., Pancrazzi A., Guerini V., Barosi G., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008; 112(3): 844-7. doi:10.1182/blood-2008-01-135897.

Guglielmelli P., Pancrazzi A., Bergamaschi G., Rosti V., Villani L., Antonioli E., et al. Anaemia characterizes patients with myelofibrosis harbouring Mpl mutation. Br. J. Haematol. 2007; 137(3): 244-7.

Carobbio A., Thiele J., Passamonti F., Rumi E., Ruggeri M., Rodeghiero F., et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22): 5857-9. doi: 10.1182/blood-2011-02-339002.

Passamonti F., Rumi E., Pietra D., Elena C., Boveri E., Arcaini L., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010; 24(9): 1574-9. doi: 10.1038/leu.2010.148.

Passamonti F., Elena C., Schnittger S., Skoda R.C., Green A.R., Girodon F., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011; 117(10): 2813-6. doi: 10.1182/blood-2010-11-316810.

Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile ofhomozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007; 110(3): 840-6.

Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et.al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 2013; 369(25): 2379-90. doi: 10.1056/NEJMoa1311347.

Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 2013; 69(25): 2391-405. doi: 10.1056/NEJMoa1312542.

Tefferi A., Lasho T.L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., et al. IDH1 and IDH2 mutation studies in1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010; 24(7): 1302-9. doi: 10.1038/leu.2010.113.

Tefferi A., Pardanani A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009; 23(5): 905-11. doi:10.1038/leu.2009.47.

Brecqueville M., Rey J., Bertucci F., Coppin E., Finetti P., Carbuccia N., et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012; 51(8): 743-55. doi: 10.1002/gcc.21960.

Stegelmann F., Bullinger L., Schlenk R.F., Paschka P., Griesshammer M., Blersch C., et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011; 25(7): 1217-9 doi: 10.1038/leu.2011.77.

Guglielmelli P., Biamonte F., Score J., Hidalgo-Curtis C., Cervantes F., Maffioli M., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011; 118(19): 5227-34. doi:10.1182/blood-2011-06-363424.

Varricchio L., Mancini A., Migliaccio A.R. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert. Rev. Hematol. 2009; 2(3): 315-34.

Cho S.Y., Xu M., Roboz J., Lu M., Mascarenhas J., Hoffman R. The Effect of CXCL12 Processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res. 2010; 70(8): 3402-10. doi: 10.1158/0008-5472.CAN-09-3977.

Massa M., Rosti V., Ramajoli I., Campanelli R., Pecci A., Viarengo G., et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J. Clin. Oncol. 2005; 23(24): 5688-95.

Schmitt A., Jouault H., Guichard J. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000. 96(4): 1342-7.

Cervantes F., Alvarez-Larran A., Talarn C., Gomez M., Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br. J. Haematol. 2002; 118(3): 78690. doi: 10.1046/j.1365-2141.2002.03688.x

Passamonti F., Rumi E., Arcaini L., Boveri E., Elena C., Pietra D., et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008; 93(11): 1645-51. doi: 10.3324/haematol.13346.

Wolanskyj A.P, Schwager S.M., McClure R.F., Larson D.R., Tefferi A. Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors. Mayo Clin. Proc. 2006; 81(2): 159-66.

Kiladjian J.J., Rain J.D., Bernard J.F., Briere J., Chomienne C., Fenaux P Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost. 2006; 32(4, Pt 2): 417-21.

Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 2011; 29(10): 1356-63.

Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007; 110(4): 1092-7. doi:10.1182/blood-2007-04-083501

Mossuz P., Girodon F., Donnard M., Latger-Cannard V., Dobo I., Boiret N., et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004; 89(10): 1194-8.

Crisa E., Venturino E., Passera R., Prina M., Schinco P., Borchiellini A. , et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann. Hematol. 2010; 89(7): 691-9. doi: 10.1007/s00277-009-0899-z.

Diehn F., Tefferi A. Pruritus in polycythaemia vera: Prevalence, laboratory correlates and management. Br. J. Haematol. 2001; 115(3): 619-21.

Finazzi G., Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008; 22(8): 1494-502.

Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E., et al. Development and validation of an International Prognostic Score of thrombosis in WHO-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120(26): 5128-33. doi: 10.1182/blood-2012-07-444067.

Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 2012; 87(3): 285-93. doi: 10.1002/ajh.23135.

Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M., et al. European LeukemiaNet. Philadelphianegative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol 2011; 29(6): 761-70. doi: 10.1200/JCO.2010.31.8436.

Michiels J.J., Berneman Z., Schroyens W., Finazzi G., Budde U., Vliet H.H. The paradox of platelet activation and impaired function: plateletvon Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin. Thromb. Hemost. 2006; 32(6): 589-604.

Budde U., Schaefer G., Mueller N., Egli H., Dent J., Ruggeri Z., et al. Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood. 1984; 64(5): 981-5.

Keohane C., Radia D.H., Harrison C.N. Treatment and management of myelofibrosis in the era of JAK inhibitors. Biologics. 2013; 7: 189-98. doi:10.2147/BTT.S34942.

Marchioli R., Finazzi G., Specchia G., Cacciola R., Cavazzina R., Cilloni D., et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl. J. Med. 2013; 368(1): 22-33. doi: 10.1056/NEJMoa1208500.

Landolfi R., Marchioli R., Kutti J., Gisslinger H., Tognoni G., Patrono C., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 2004; 350(2): 114-24.

Pascale S., Petrucci G., Dragani A., Habib A., Zaccardi F., Pagliaccia F., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012; 119(15): 3595-603. doi: 10.1182/blood-2011-06-359224.

Finazzi G. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol. Biol. 2004; 52(5): 285-8.

Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management Am. J. Hematol. 2013; 88(6): 507-16. doi: 10.1002/ajh.23417.

Passamonti F. How I treat polycythemia vera. Blood. 2012. 120(2). 27584. doi: 10.1182/blood-2012-02-366054.

Fruchtman S.M., Mack K., Kaplan M.E., Peterson P., Berk P.D., Wasserman L.R. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin. Hematol. 1997; 34(1): 17-23.

Barosi G. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br. J. Haematol. 2010; 148(6): 961-3.

Quintas-Cardama A., Kantarjian H., Manshouri T., Luthra R., Estrov Z., Pierce S., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol. 2009; 27(32): 5418-24. doi: 10.1200/JCO.2009.23.6075.

Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcrabl-negative myeloproliferative neoplasms. Leukemia. 2008; 22(11): 1990-8. doi: 10.1038/leu.2008.280.

Mazza J.J. Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial. “Leukemia and Hematosarcoma” Cooperative Group, European Organization for Research on Treatment of Cancer (EORTC). Br. J. Cancer. 1981; 44(1): 75-80.

Barosi G., Mesa R., Finazzi G., Harrison C., Kiladjian J.J., Lengfelder E., et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121(23): 4778-81. doi: 10.1182/blood-2013-01-478891.

Mesa R.A., Silverstein M.N., Jacobsen S.J., Wollan P.C., Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995. Am. J. Hematol. 1999; 61(1): 10-5.

Tefferi A., Solberg L.A., Silverstein M.N. A clinical update in polycythemia vera and essential thrombocythemia. Am. J. Med. 2000; 109(2): 141-9.

Alvarez-Larran A., Cervantes F., Bellosillo B., Giralt M., Julia A., Hernandez-Boluda J.C., et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007; 21(6): 1218-23.

Palandri F., Polverelli N., Ottaviani E., Castagnetti F., Baccarani M., Vianelli N. Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica. 2010; 95(6): 1038-40. doi: 10.3324/haematol.2009.019190.

Shuvaev V.A. Essential thrombocythemia - population analysis, a single center 10-years’experience. ELN Information letter. 2013; 1: 21. http://www.leukemia-net.org/content/home/e_newsletter/index_eng.html.

Thiele J., Kvasnicka H.M., Vardiman J.W., Orazi A., Franco V., Gisslinger H., et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J. Clin. Oncol. 2009; 27(34): 220-1. doi: 10.1200/JCO.2009.24.3485.

Schmitt-Graeff A.H., Teo S.S., Olschewski M., Schaub F., Haxelmans S., Kirn A., et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008; 93(1): 34-40. doi: 10.3324/haematol.11581.

Kvasnicka H.M., Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am. J. Hematol. 2010; 85(1): 62-9.